How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Open accessThe DOI matches its Crossref record; 90 of the 92 references it cites were found in a registry or an index.
Abstract
We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006-August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit hyperactivity disorder, and Tourette`s disorder. Outcome variables were too heterogeneous to conduct a meta-analysis. A narrative synthesis method was applied. The study quality was assessed using the risk-of-bias tool and SIGN-checklists. THC- and CBD-based medicines, given as adjunct to pharmaco- and psychotherapy, were associated with improvements of several symptoms of mental disorders, but not with remission. Side effects occurred, but severe adverse effects were mentioned in single cases only. In order to provide reliable treatment recommendations, more and larger RCTs with follow-up assessments, consistent outcome measures and active comparisons are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Kyu, H. H., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32335-3 · Cited by 4,081
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“Keywords Mental disorders · Cannabis · Cannabinoids · THC · CBD · Medical cannabis · Treatment Introduction Mental disorders are among the leading causes of health impairments [25, 77, 89, 91] involving significant changes in thinking, perception, emotion, behavior and relationships [4].”
BackgroundThe global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013
Steel, Z., Marnane, C., Iranpour, C., Chey, T., Jackson, J. W., Patel, V., & Silove, D. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu038 · Cited by 2,846 · cited 1×
“Keywords Mental disorders · Cannabis · Cannabinoids · THC · CBD · Medical cannabis · Treatment Introduction Mental disorders are among the leading causes of health impairments [25, 77, 89, 91] involving significant changes in thinking, perception, emotion, behavior and relationships [4].”
BackgroundAdverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed Central · Cited by 2,760
A critical review of visual analogue scales in the measurement of clinical phenomena
Wewers, M. E., & Lowe, N. K. (1990) · Research in Nursing & Health · doi:10.1002/nur.4770130405 · Cited by 2,580
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32130-x · Cited by 2,083
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Groce, E. (2018) · Journal of Medical Regulation · doi:10.30770/2572-1852-104.4.32 · Cited by 1,330
An Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234 · cited 1×
“However, growing interest in the substance as medicine was renewed in the 1990s with the discovery of cannabinoid receptors 1 and 2 (CB1 and CB2, respectively), endogenous ligands (endocannabinoids; N-arachidonoylethanolamine (anandamide/AEA) and 2-arachidonoylglycerol (2-AG)), and enzymes as part of an endogenous can…”
BackgroundWhiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116820 · Cited by 1,175 · cited 1×
“Keywords Mental disorders · Cannabis · Cannabinoids · THC · CBD · Medical cannabis · Treatment Introduction Mental disorders are among the leading causes of health impairments [25, 77, 89, 91] involving significant changes in thinking, perception, emotion, behavior and relationships [4].”
BackgroundHuman Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Pharmacology and effects of cannabis: A brief review
Ashton, C. H. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.101 · Cited by 934
Lewin, S., Glenton, C., Munthe-Kaas, H., Carlsen, B., Colvin, C. J., Gülmezoglu, M., Noyes, J., Booth, A., Garside, R., & Rashidian, A. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001895 · Cited by 866
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515
Endocannabinoid signalling in reward and addiction
Parsons, L. H., & Hurd, Y. L. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4004 · Cited by 481
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
RODRÍGUEZ de FONSECA, F., DEL ARCO, I., BERMUDEZ-SILVA, F. J., BILBAO, A., CIPPITELLI, A., & NAVARRO, M. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 407 · cited 3×
“Endocannabinoids are one of the most important systems controlling both excitatory and inhibitory neurotransmission, as well as neuroplasticity [72].”
BackgroundHill, M. N., & Tasker, J. G. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.030 · Cited by 341
Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330
Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.11.002 · Cited by 321 · cited 3×
“The scientific literature shows, that among all cannabisbased medicines, THC-based preparations have been tested most frequently as treatment for mental disorders: Nabiximols (4 RCTs) [2, 18, 79, 80], dronabinol (6 RCTs) [5–7, 12, 42, 43, 48, 85], THC (5 RCTs) [1, 60–62, 82, 83], and nabilone [36].”
BackgroundThe health and social effects of nonmedical cannabis use.
Hall, W., Renstrom, M., & Poznyak, V. B. (2016) · Cited by 315
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
A historical overview of chemical research on cannabinoids
Mechoulam, R., & Hanuš, L. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00184-5 · Cited by 282
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-25028 · Cited by 256
Boggs, D. L., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B., Schnakenberg Martin, A. M., Thurnauer, H., Davies, A., D’Souza, D. C., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4885-9 · Cited by 242
Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232
Hofmann, S. G., & DiBartolo, P. M. (2000) · Behavior Therapy · doi:10.1016/s0005-7894(00)80027-1 · Cited by 226
The endocannabinoid system: emotion, learning and addiction
Moreira, F. A., & Lutz, B. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00104.x · Cited by 222
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
Review of the neurological benefits of phytocannabinoids
Maroon, J., & Bost, J. (2018) · Surgical Neurology International · doi:10.4103/sni.sni_45_18 · Cited by 203
Test–retest reliability of the Eating Disorder Inventory 2
Thiel, A., & Paul, T. (2006) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.02.015 · Cited by 185
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial
Cooper, R. E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., & Asherson, P. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.05.005 · Cited by 175
The MATRICS Consensus Cognitive Battery (MCCB): Clinical and cognitive correlates
August, S. M., Kiwanuka, J. N., McMahon, R. P., & Gold, J. M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.015 · Cited by 170
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial
van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R.-J., Kramers, C., Feuth, T., Rosenberg, P. B., van der Marck, M. A., & Olde Rikkert, M. G. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001675 · Cited by 164
The uptake by cells of 2‐arachidonoylglycerol, an endogenous agonist of cannabinoid receptors
Bisogno, T., Maccarrone, M., De Petrocellis, L., Jarrahian, A., Finazzi‐Agrò, A., Hillard, C., & Di Marzo, V. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02072.x · Cited by 160
The endocannabinoid system and psychiatric disorders
Parolaro, D., Realini, N., Viganò, D., Guidali, C., & Rubino, T. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.018 · Cited by 160
Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial
Andries, A., Frystyk, J., Flyvbjerg, A., & Støving, R. K. (2014) · International Journal of Eating Disorders · doi:10.1002/eat.22173 · Cited by 158
Keefe, R. S. E., Poe, M., Walker, T. M., & Harvey, P. D. (2006) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390500360539 · Cited by 156
Risks Associated With the Non-Medicinal Use of Cannabis
Hoch, E., Bonnet, U., Thomasius, R., Ganzer, F., Havemann-Reinecke, U., & Preuss, U. W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0271 · Cited by 128
Self-citationTrigo, J. M., Soliman, A., Quilty, L. C., Fischer, B., Rehm, J., Selby, P., Barnes, A. J., Huestis, M. A., George, T. P., Streiner, D. L., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0190768 · Cited by 122
The validity of instruments measuring tic severity in Tourette's syndrome
WALKUP, J. T., ROSENBERG, L. A., BROWN, J., & SINGER, H. S. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199205000-00013 · Cited by 117
Levin, F. R., Mariani, J. J., Pavlicova, M., Brooks, D., Glass, A., Mahony, A., Nunes, E. V., Bisaga, A., Dakwar, E., Carpenter, K. M., et al. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.025 · Cited by 109 · cited 3×
“[43] assessed abstinence (= 21 consecutive days), withdrawal, craving, and adverse events.”
BackgroundTetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial
van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R., Feuth, T. B., van der Marck, M. A., & Rikkert, M. G. M. O. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.07.011 · Cited by 108
Bisaga, A., Sullivan, M. A., Glass, A., Mishlen, K., Pavlicova, M., Haney, M., Raby, W. N., Levin, F. R., Carpenter, K. M., Mariani, J. J., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.013 · Cited by 101
Ahmed, A. I. A., van den Elsen, G. A. H., Colbers, A. P. H., Kramers, C., Burger, D. M., van der Marck, M. A., & Rikkert, M. G. M. O. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3889-y · Cited by 99
Therapeutic Potential of Cannabinoids in Psychosis
Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.018 · Cited by 99
Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?
Fowler, C. J., Rojo, M. L., & Rodríguez‐Gaztelumendi, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.021 · Cited by 97
Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Trigo, J. M., Lagzdins, D., Rehm, J., Selby, P., Gamaleddin, I., Fischer, B., Barnes, A. J., Huestis, M. A., & Le Foll, B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.020 · Cited by 97 · cited 4×
“The scientific literature shows, that among all cannabisbased medicines, THC-based preparations have been tested most frequently as treatment for mental disorders: Nabiximols (4 RCTs) [2, 18, 79, 80], dronabinol (6 RCTs) [5–7, 12, 42, 43, 48, 85], THC (5 RCTs) [1, 60–62, 82, 83], and nabilone [36].”
BackgroundInfluentialThe endocannabinoid system in mental disorders: Evidence from human brain studies
Ibarra‐Lecue, I., Pilar-Cuéllar, F., Muguruza, C., Florensa-Zanuy, E., Díaz, Á., Urigüen, L., Castro, E., Pazos, Á., & Callado, L. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.009 · Cited by 91 · cited 2×
“Preclinical and clinical data support the involvement of the eCB in the etiopathogenesis of mental disorders [24, 35, 44, 73].”
BackgroundPouwer, F., van der Ploeg, H. M., Adèr, H. J., Heine, R. J., & Snoek, F. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.12.2004 · Cited by 89
Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
Endocannabinoids and Mental Disorders
Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 80
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans
Lofwall, M. R., Babalonis, S., Nuzzo, P. A., Elayi, S. C., & Walsh, S. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.05.002 · Cited by 70
Cannabinoid Modulation of the Stressed Hippocampus
Scarante, F. F., Vila-Verde, C., Lopes, V. D., Ferreira‐Junior, N. C., Guimarães, F. S., & Campos, A. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00411 · Cited by 70
Müller-Vahl, K. R., Koblenz, A., Jöbges, M., Kolbe, H., Emrich, H. M., & Schneider, U. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-15191 · Cited by 66
Family Functioning, Coping, and Distress in Families With Serious Mental Illness
Crowe, A., & Lyness, K. P. (2013) · The Family Journal · doi:10.1177/1066480713513552 · Cited by 66
Treatment of patients with severe and enduring eating disorders
Hay, P., & Touyz, S. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000191 · Cited by 60
Boggs, D. L., Kelly, D. L., McMahon, R. P., Gold, J. M., Gorelick, D. A., Linthicum, J., Conley, R. R., Liu, F., Waltz, J., Huestis, M. A., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.009 · Cited by 53
Safety of oral dronabinol during opioid withdrawal in humans
Jicha, C. J., Lofwall, M. R., Nuzzo, P. A., Babalonis, S., Elayi, S. C., & Walsh, S. L. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.031 · Cited by 49
Andries, A., Gram, B., & Støving, R. K. (2014) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-014-0132-5 · Cited by 42
Andries, A., Frystyk, J., Flyvbjerg, A., & Støving, R. K. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.07.006 · Cited by 42
Mücke, M., Carter, C., Cuhls, H., Prüß, M. S., Radbruch, L., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0085-2 · Cited by 41 · cited 1×
“1 3 Results of individual studies Dementia (F0 ICD-10) 1 SR [59] of 1 RCT and 3 additional RCTs were identified [1, 82–85].”
BackgroundKaranian, D. A., & Bahr, B. A. (2006) · Current Molecular Medicine · doi:10.2174/156652406778194991 · Cited by 25
van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R. J., Kramers, K., Feuth, T. B., Rikkert, M. G. M. O., & van der Marck, M. A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.498 · Cited by 9
Fattore, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00022-9 · Cited by 1
(1997) · doi:10.1002/(sici)1099-1166(199709)12:9<913::aid-gps663>3.0.co;2-d
Research works printed but not linked: 5
- Higgins JPT Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] 2011 London The Cochrane Collaboration
- Hoch E Friemel C Schneider M Cannabis: Potenzial und Risiko [Cannabis: Potential and Risks] 2018 Heidelberg Springer
- National Research C, Institute of Medicine Committee on the Prevention of Mental D, Substance Abuse Among Children Y, Young Adults: Research A, Promising I (2009) The National Academies Collection: Reports funded by National Institutes of Health. In: O’Connell ME, Boat T, Warner KE (eds) Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities. National Academies Press (US) 20662125
- OCEBM The oxford levels of evidence 2011 2 Oxford Oxford Centre for Evidence-Based Medicine
- W orld Health Organization ICD-10: international statistical classification of diseases and related health problems/World Health Organization 2004 Geneva World Health Organization
Cited by
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Self-citationHall, W., Stjepanović, D., Caulkins, J., Lynskey, M., Leung, J., Campbell, G., & Degenhardt, L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31789-1 · Cited by 357
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Gene-Environment Interactions in Schizophrenia: A Literature Review
Wahbeh, M. H., & Avramopoulos, D. (2021) · Genes · doi:10.3390/genes12121850 · Cited by 214
“Another group also found that there was an additive interaction between schizophrenia PRS scores and regular cannabis use [87].”
BackgroundCannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01880-2 · Cited by 139
“In these studies, THC and/or CBD were administered with other pharmacotherapies and/or psychotherapy [15].”
Self-citation
Metadata
- Authors
- Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O.
- Affiliations
- LMU Klinikum (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Hoch, Eva
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2019-01-31
- Volume
- 269
- Issue
- 1
- Pages
- 87-105
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC6595000
- OpenAlex
- W2912950775
- Cited by
- 131
- References
- 92
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 17 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-04-05)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Bundesministerium f?r Gesundheit
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- medical cannabis, cannabis-based medicines, mental illness, schizophrenia, psychosis, post-traumatic stress disorder, social anxiety, anorexia nervosa, attention deficit hyperactivity disorder, Tourette syndrome, dementia, THC, CBD, adjunctive therapy, efficacy, safety, adverse effects
- MeSH terms
- Mental Disorders, Cannabidiol, Humans, Dronabinol, Cannabinoid Receptor Modulators, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.